Treatment and prevention of acute kidney injury using anti-alpha v beta 5 antibodies

Patent metadata

Field	Value
Publication number	US-2016017041-A1
Application number	US-201414770522-A
Country	US
Kind code	A1
Filing date	Mar 13, 2014
Priority date	Mar 15, 2013
Publication date	Jan 21, 2016
Grant date	—

Abstract

Methods of using antibodies and antibody fragments that specifically bind αvβ5 or β5 to treat or prevent acute kidney injury and/or its sequelae are disclosed.

First claim

1 . A method for treating, preventing, or reducing the severity of acute kidney injury in a human subject in need thereof, the method comprising administering to the human subject an effective amount of an antibody or an antigen-binding fragment thereof that specifically binds to the αvβ5 integrin.

2 . The method of claim 1 , wherein the antibody or the antigen-binding fragment thereof competes with an antibody produced by the hybridoma deposited as ATCC Deposit No. PTA-5817.

3 . The method of claim 1 , wherein the antibody or the antigen-binding fragment thereof comprises the heavy chain variable region CDR1, CDR2, and CDR3 according to the Kabat definition of the antibody produced by the hybridoma deposited as ATCC Deposit No. PTA-5817.

4 . The method of claim 3 , wherein the antibody or the antigen-binding fragment thereof further comprises the light chain variable region CDR1, CDR2, and CDR3 according to the Kabat definition of the antibody produced by the hybridoma deposited as ATCC Deposit No. PTA-5817.

5 . The method of claim 1 , wherein the antibody or the antigen-binding fragment thereof is a humanized form of the antibody produced by the hybridoma deposited as ATCC Deposit No. PTA-5817.

6 . The method of claim 1 , wherein the antibody or the antigen-binding fragment thereof is administered intravenously, subcutaneously, or intraarterially.

7 . The method of claim 1 , wherein the human subject has been identified as having acute kidney injury based on the Acute Kidney Injury Network criteria or Risk/Injury/Failure/Loss/ESRD criteria.

8 . The method of claim 1 , wherein the human subject has been identified as having an elevated level of serum creatinine, plasma creatinine, urine creatinine, or blood urea nitrogen, compared to a healthy control subject.

9 . The method of claim 1 , wherein the human subject has been identified as having an elevated level of serum or urine neutrophil gelatinase-associated lipocalin, serum or urine interleukin-18, serum or urine cystatin C, or urine KIM-1, compared to a healthy control subject.

10 . The method of claim 1 , wherein the acute kidney injury is an ischemic acute kidney injury.

11 . The method of claim 10 , wherein the human subject has been identified as having reduced effective arterial volume.

12 . The method of claim 10 , wherein the human subject has been identified as having intravascular volume depletion.

13 . The method of claim 12 , wherein the intravascular volume depletion is due to hemorrhage, gastrointestinal loss, renal loss, skin and mucous membrane loss, nephrotic syndrome, cirrhosis, or capillary leak.

14 . The method of claim 10 , wherein the human subject has been identified as having reduced cardiac output.

15 . The method of claim 14 , wherein the reduced cardiac output is due to cardiogenic shock, pericardial disease, congestive heart failure, valvular heart disease, pulmonary disease, or sepsis.

16 . The method of claim 10 , wherein the human subject has been identified as having systemic vasodilation.

17 . The method of claim 16 , wherein the systemic vasodilation is caused by cirrhosis, anaphylaxis, or sepsis.

18 . The method of claim 10 , wherein the human subject has been identified as having renal vasoconstriction.

19 . The method of claim 18 , wherein the renal vasoconstriction is caused by early sepsis, hepatorenal syndrome, acute hypercalcemia, a drug, or a radiocontrast agent.

20 . The method of claim 1 , wherein the acute kidney injury is a nephrotoxic acute kidney injury.

21 . The method of claim 20 , wherein the human subject has been exposed to a nephrotoxin.

22 . The method of claim 21 , wherein the nephrotoxin is a nephrotoxic drug selected from the group consisting of an antibiotic, a chemotherapeutic agent, a calcineurin inhibitor, amphotericin B, and a radiographic contrast agent.

23 . The method of claim 21 , wherein the nephrotoxin is an illicit drug or a heavy metal.

24 . The method of claim 1 , wherein the human subject has undergone a trauma injury or a crush injury.

25 . The method of claim 1 , wherein the human subject has undergone an organ transplant surgery.

26 . The method of claim 25 , wherein the organ transplant surgery is kidney transplant surgery or heart transplant surgery.

27 . The method of claim 1 , wherein the human subject has undergone a surgery complicated by hypoperfusion.

28 . The method of claim 1 , wherein the human subject has undergone cardiothoracic surgery or a vascular surgery.

29 . The method of claim 1 , wherein the human subject has taken medication that interferes with normal emptying of the bladder.

30 . The method of claim 29 , wherein the medication is an anticholinergic.

31 . The method of claim 1 , wherein the human subject has benign prostatic hypertrophy.

32 . The method of claim 1 , wherein the human subject has a cancer.

33 . The method of claim 32 , wherein the cancer is prostate cancer, ovarian cancer, or colorectal cancer.

34 . The method of claim 1 , wherein the human subject has a kidney stone.

35 . The method of claim 1 , wherein the human subject has an obstructed urinary catheter.

36 . The method of claim 1 , wherein the human subject has taken a drug that causes or leads to crystalluria, a drug that causes or leads to myoglobinuria, or a drug that causes or leads to cystitis.

37 . The method of claim 1 , wherein the human subject is administered a second therapeutic agent selected from the group consisting of an αvβ5 integrin inhibitor, an αvβ6 integrin inhibitor, a CXCR4 antagonist, an IL-6 inhibitor, an IL-1α inhibitor, an IL-12 inhibitor, a MIP-1-α inhibitor, AP214, THR-184, QPI-1002, a human alkaline phosphatase, an anti-apoptosis agent, an anti-necrosis agent, an anti-inflammatory agent, an anti-sepsis agent, a growth factor, a vasodilator, a free radical scavenger, neutrophil gelatinase-associated lipocalin, a C5a receptor antagonist, and α-melanocyte-stimulating hormone.

Assignees

• Biogen Ma Inc

Inventors

• Violette Shelia M
• Maroni Bradley J

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P37/08

  Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14) · CPC title

• A61P7/04

  Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents · CPC title

• A61P31/04

  Antibacterial agents · CPC title

• A61P25/36

  Opioid-abuse · CPC title